Skip to Main Content

Amer Zeidan, MBBS, MHS, appointed inaugural Chief of the Division of Hematologic Malignancies

March 07, 2024

After an extensive national search, Amer Zeidan, MBBS, MHS, has been appointed inaugural Chief of the Division of Hematologic Malignancies at Yale Cancer Center. Dr. Zeidan is from Jordan and received his medical degree from The University of Jordan School of Medicine, followed by a preliminary year internship in Jordan. He then completed a residency in internal medicine at Rochester General Hospital followed by three years as an academic hospitalist at Rochester General Hospital. Dr. Zeidan then pursued a fellowship in hematology and medical oncology at Johns Hopkins Medicine, followed by an additional year as a fellow focused on myelodysplastic syndromes. In 2014, Dr. Zeidan joined the Yale faculty as an Assistant Professor of Medicine (Hematology) and was promoted to Associate Professor in 2019. He has more than 330 peer-reviewed publications, is the principal investigator on numerous phase II and III clinical trials and has rapidly become a leading clinical expert and trialist in the areas of acute myeloid leukemia and myelodysplastic syndromes.

Dr. Zeidan brings a tremendous skill set to his new position. He is an accomplished clinician, clinical and translational investigator, mentor, and educator. He is bright, insightful, and dedicated. He is passionate about making a difference for patients with hematologic malignancies. Dr. Zeidan is also committed to building a world-class hematologic malignancy program at Yale Cancer Center and Smilow Cancer Hospital. He enjoys the confidence of his colleagues in the leukemia, lymphoma, myeloma, and transplant groups, as well as the senior leadership in Yale Cancer Center, Smilow Cancer Hospital, and Yale School of Medicine. Of note, Dr. Zeidan will continue to lead the leukemia program and his position as Assistant Director in the Clinical Trials Office.

Please join us in welcoming Dr. Zeidan into this new role.

Submitted by Eliza Folsom on March 07, 2024